Novartis takes hit from private label
This article was originally published in The Tan Sheet
A shift in U.S. consumer spending toward private label products stymied Novartis Consumer Healthcare's sales in its fiscal 2008 second quarter, the Swiss company says July 17. However, "emerging markets and strategic brands helped OTC offset lower sales in the U.S" so the division still pulled in $1.5 billion in net sales, a 15 percent increase in the U.S., or a 3 percent increase in local currency, compared to the year-ago period, Novartis says. Despite a tough quarter for consumer sales, net sales for the firm grew ahead of expectations to $10.7 billion - a 14 percent increase in U.S. dollars, or 5 percent in local currencies, primarily attributed to Novartis' pharmaceutical division overcoming the impact of 2007 challenges in U.S. vaccines and diagnostics, the firm says. Novartis' bad news comes as private labeler Perrigo reports expansion plans and expects a boost from consumers using less expensive store brand products (1"The Tan Sheet" July 14, 2008, p. 3)...
You may also be interested in...
Current challenging economic conditions may help Perrigo's private label business grow, unlike the sales slumps that commonly hit consumer product companies when spending slows
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.